| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5585397 | GLAXOSMITHKLINE | Sulfonamide inhibitors of aspartyl protease |
Dec, 2013
(10 years ago) | |
| US5646180 | GLAXOSMITHKLINE | Treatment of the CNS effects of HIV |
Jul, 2014
(9 years ago) | |
| US5723490 | GLAXOSMITHKLINE | THF-containing sulfonamide inhibitors of aspartyl protease |
Mar, 2015
(9 years ago) | |
| US6730679 | GLAXOSMITHKLINE | Pharmaceutical formulations |
Nov, 2017
(6 years ago) | |
Agenerase is owned by Glaxosmithkline.
Agenerase contains Amprenavir.
Agenerase has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Agenerase are:
- US5585397
- US5646180
- US5723490
- US6730679
Agenerase was authorised for market use on 15 April, 1999.
Agenerase is available in capsule;oral, solution;oral dosage forms.
Agenerase can be used as treatment of hiv infection.
The generics of Agenerase are possible to be released after 11 November, 2017.
Drugs and Companies using AMPRENAVIR ingredient
Market Authorisation Date: 15 April, 1999
Treatment: Treatment of hiv infection
Dosage: CAPSULE;ORAL; SOLUTION;ORAL
More Information on Dosage
AGENERASE family patents
